1
Clinical Trials associated with GSK-3903133ASafety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.
The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM [CNE] vaccine), made using a new technology, when administered intramuscularly (IM) on a 0, 2, 6 *-month schedule to healthy adults.
* There will be no vaccinations with the third dose of any of the study treatments.
100 Clinical Results associated with GSK-3903133A
100 Translational Medicine associated with GSK-3903133A
100 Patents (Medical) associated with GSK-3903133A
100 Deals associated with GSK-3903133A